WELL Health Technologies Corp (WELL – Research Report), the Healthcare company was revisited today, and remains undervalued for at least one analyst on the street. Analyst Justin Keywood from Stifel Nicolaus reiterated a Buy rating, with a C$12.00 price target.
According to TipRanks.com, Keywood is a 1-star analyst with an average return of -0.9% and a 38.2% success rate. Keywood covers the Healthcare sector, focusing on stocks such as Andlauer Healthcare Group, Cipher Pharmaceuticals, and Knight Therapeutics.
Currently, the analyst consensus on WELL Health Technologies Corp is a Strong Buy with an average price target of C$8.60, a 98.6% upside from current levels. In a report released yesterday, Scotiabank also maintained a Buy rating on the stock with a C$6.50 price target.
The company has a one-year high of C$5.94 and a one-year low of C$2.56. Currently, WELL Health Technologies Corp has an average volume of 716.4K.
WELL Health Technologies Corp is the owner and operator of a portfolio of Primary Hclinics delivering healthcare-related services It operates through below segments: Clinical services, Digital services, and others. It also engages in the Electronic Medical Records business that supports the digitization of clinics. Its objective is to empower doctors to provide the best and most advanced care possible leveraging the latest trends in digital health.
The company’s shares closed last Friday at C$4.26.
Read More on TSE:WELL:
- WELL Health’s Cycura Announces Two Tuck-In Acquisitions to Enhance Patient Data Protection and Appoints New Management
- WELL Health Completes Clinic Acquisition and Investment Transactions with HEALWELL AI Inc. (formerly MCI Onehealth), and Forms Strategic Alliance Focused on Developing AI Enabled Disease Detection and Preventative Care Tools for Care Providers
